Regeneron Pharma announced earnings per share of $9.53 on revenue of $2.42B. Analysts polled by Investing.com anticipated EPS of $8.23 on revenue of $2.41B.
Regeneron Pharma shares are up 3.26% from the beginning of the year, still down 24.95% from its 52 week high of $664.64 set on July 20, 2020. They are broadly in line with the S&P 500 which is up 3.08% from the start of the year.
Regeneron Pharma’s report follows an earnings beat by J&J on January 26, who reported EPS of $1.86 on revenue of $22.48B, compared to forecasts EPS of $1.82 on revenue of $21.66B.
Roche Holding ADR had missed expectations on Monday with fourth quarter EPS of $1.21 on revenue of $15.88B, compared to forecast for EPS of $1.28 on revenue of $17.17B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
